nach oben

rheuma plus

Erschienen in:

04.01.2021 | Rheumatologie | Aus der Praxis

ANCA-assoziierte Vaskulitiden nach Erreichen einer Remission

verfasst von: Prof. Dr. med. B. Hellmich

Erschienen in: rheuma plus | Ausgabe 2/2021

Einloggen, um Zugang zu erhalten

Auszug

Rituximab (RTX) wurde für die remissionserhaltende Therapie bei GPA/MPA (Granulomatose mit Polyangiitis/mikroskopische Polyangiitis) zugelassen. Welchen Stellenwert haben jetzt Methotrexat (MTX) und Azathioprin (AZA), welchen RTX? …

Vorheriger Artikel Arthritis anders? – Neues zu seronegativen Spondarthritiden

Alberici F, Smith RM, Jones RB et al (2015) Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitis. Rheumatology (Oxford) 54:1153–1160CrossRef

Chan V, Charles BG, Tett SE (2005) Population pharmacokinetics and association between A77 1726 plasma concentrations and disease activity measures following administration of leflunomide to people with rheumatoid arthritis. Br J Clin Pharmacol 60:257–264CrossRef

Chanouzas D, Mcgregor JAG, Nightingale P et al (2019) Intravenous pulse methylprednisolone for induction of remission in severe ANCA associated Vasculitis: a multi-center retrospective cohort study. BMC Nephrol 20:58CrossRef

Charles P, Dechartres A, Terrier B et al (2020) Reducing the initial number of rituximab maintenance-therapy infusions for ANCA-associated vasculitides: randomized-trial post-hoc analysis. Rheumatology (Oxford). https://doi.org/10.1093/rheumatology/kez063.029CrossRef

Charles P, Perrodeau E, Bonnotte B et al (2019) Comparions between long-term and conventional rituximab-maintenance treatments: results of a plecebo-controlled randomized trial. Arthritis & rheumatology (Hoboken, N.J.) 71 (Suppl 10). https://acrabstracts.org/comparison-between-long-termn-and-conventional-rituximab-maintenance-treatments-results-of-a-placebo-controlled-randomized-trial/. Zugegriffen: 30. März 2020

Charles P, Terrier B, Perrodeau E et al (2018) Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2). Ann Rheum Dis 77:1143–1149CrossRef

Csernok E, Hellmich B (2020) Usefulness of vasculitis biomarkers in the era of the personalized medicine. Autoimmun Rev 19(5):102514CrossRef

Csernok E, Mahrhold J, Hellmich B (2018) Anti-neutrophil cytoplasm antibodies (ANCA): recent methodological advances-lead to new consensus recommendations for ANCA detection. J Immunol Methods 456:1–6CrossRef

De Groot K, Aries PM, Haubitz M et al (2020) Anti-B-Zell Therapie zur Remissionserhaltung bei Granulomatose mit Polyangiitis und mikroskopischer Polyangiitis. Dtsch Med Wochenschr 145:40–46CrossRef

10.

De Joode AAE, Sanders JSF, Puechal X et al (2017) Long term azathioprine maintenance therapy in ANCA-associated vasculitis: combined results of long-term follow-up data. Rheumatology. https://doi.org/10.1093/rheumatology/kex281CrossRefPubMed

11.

Deshayes S, Martin Silva N, Khoy K et al (2019) Clinical impact of subgrouping ANCA-associated vasculitis according to antibody specificity beyond the clinicopathological classification. Rheumatology (Oxford) 58:1731–1739CrossRef

12.

Faurschou M, Westman K, Rasmussen N et al (2012) Brief Report: long-term outcome of a randomized clinical trial comparing methotrexate to cyclophosphamide for remission induction in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 64:3472–3477. https://doi.org/10.1002/art.34547CrossRefPubMed

13.

Flossmann O, Berden A, De Groot K et al (2011) Long-term patient survival in ANCA-associated vasculitis. Ann Rheum Dis 70:488–494CrossRef

14.

Guillevin L, Pagnoux C, Karras A et al (2014) Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med 371:1771–1780. https://doi.org/10.1056/NEJMoa1404231CrossRefPubMed

15.

Harper L, Morgan MD, Walsh M et al (2012) Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up. Ann Rheum Dis 71:955–960. https://doi.org/10.1136/annrheumdis-2011-200477CrossRefPubMed

16.

Hiemstra TF, Walsh M, Mahr A et al (2010) Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial. JAMA 304:2381–2388CrossRef

17.

Jayne D, Blockmans D, Luqmani R et al (2019) Efficacy and safety of belimumab and azathioprine for maintenance of remission in antineutrophil cytoplasmic antibody-associated Vasculitis: a randomized controlled study. Arthritis Rheumatol 71:952–963CrossRef

18.

Jones RB, Hiemstra TF, Ballarin J et al (2019) Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: a randomised, non-inferiority trial. Ann Rheum Dis 78:399–405CrossRef

19.

Karras A, Pagnoux C, Haubitz M et al (2017) Randomised controlled trial of prolonged treatment in the remission phase of ANCA-associated vasculitis. Ann Rheum Dis 76:1662–1668CrossRef

20.

Kronbichler A, Kerschbaum J, Gopaluni S et al (2018) Trimethoprim-sulfamethoxazole prophylaxis prevents severe/life-threatening infections following rituximab in antineutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis 77:1440–1447CrossRef

21.

Lionaki S, Blyth ER, Hogan SL et al (2012) Classification of antineutrophil cytoplasmic autoantibody vasculitides: the role of antineutrophil cytoplasmic autoantibody specificity for myeloperoxidase or proteinase 3 in disease recognition and prognosis. Arthritis Rheum 64:3452–3462CrossRef

22.

Lionaki S, Hogan SL, Jennette CE et al (2009) The clinical course of ANCA small-vessel vasculitis on chronic dialysis. Kidney Int 76:644–651CrossRef

23.

Mcclure ME, Wason J, Gopaluni S et al (2019) Evaluation of PR3-ANCA status after rituximab for ANCA-associated vasculitis. J Clin Rheumatol 25:217–223CrossRef

24.

Mcgeoch L, Twilt M, Famorca L et al (2016) CanVasc recommendations for the management of antineutrophil cytoplasm antibody-associated vasculitides. J Rheumatol 43:97–120CrossRef

25.

Metzler C, Miehle N, Manger K et al (2007) Elevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in Wegener’s granulomatosis. Rheumatology (Oxford) 46:1087–1091CrossRef

26.

Montante A, Le Bras A, Pagnoux C et al (2019) Cost-effectiveness of rituximab versus azathioprine for maintenance treatment in antineutrophil cytoplasmic antibody-associated vasculitis. Clin Exp Rheumatol 37(Suppl 117):137–143PubMed

27.

Morgan MD, Szeto M, Walsh M et al (2017) Negative anti-neutrophil cytoplasm antibody at switch to maintenance therapy is associated with a reduced risk of relapse. Arthritis Res Ther 19:129CrossRef

28.

Ntatsaki E, Carruthers D, Chakravarty K et al (2014) BSR and BHPR guideline for the management of adults with ANCA-associated vasculitis. Rheumatology (Oxford) 53:2306–2309CrossRef

29.

Pagnoux C, Mahr A, Hamidou MA et al (2008) Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N Engl J Med 359:2790–2803CrossRef

30.

Pierrot-Deseilligny Despujol C, Pouchot J, Pagnoux C et al (2010) Predictors at diagnosis of a first Wegener’s granulomatosis relapse after obtaining complete remission. Rheumatology (Oxford) 49:2181–2190CrossRef

31.

Roberts DM, Jones RB, Smith RM et al (2014) Rituximab-associated hypogammaglobulinemia: Incidence, predictors and outcomes in patients with multi-system autoimmune disease. J Autoimmun 31:173–175

32.

Salmela A, Rasmussen N, Tervaert JWC et al (2017) Chronic nasal Staphylococcus aureus carriage identifies a subset of newly diagnosed granulomatosis with polyangiitis patients with high relapse rate. Rheumatology (Oxford) 56:965–972CrossRef

33.

Salmela A, Törnroth T, Poussa T et al (2018) Prognostic factors for survival and relapse in ANCA-associated vasculitis with renal involvement: a clinical long-term follow-up study. Int J Nephrol 2018:1–11. https://doi.org/10.1155/2018/6369814CrossRef

34.

Schirmer JH, Aries PM, De Groot K et al (2017) S 1 Leitlinie zur Diagnose und Therapie der ANCA-assoziierten Vaskulitiden. Z Rheumatol 76:77–104CrossRef

35.

Smith R, Jayne D, Merkel P (2019) A randomized, controlled trial of rituximab versus azathioprine after induction of remission with rituximab for patients with ANCA-associated vasculitis and relapsing disease [abstract]. Arthritis & rheumatology 71. https://acrabstracts.org/abstract/a-randomized-controlled-trial-of-rituximab-versus-azathioprine-after-induction-of-remission-with-rituximab-for-patients-with-anca-associated-vasculitis-and-relapsing-disease/. Zugegriffen: 6. Jan. 2020

36.

Solans-Laqué R, Fraile G, Rodriguez-Carballeira M et al (2017) Clinical characteristics and outcome of Spanish patients with ANCA-associated vasculitides: Impact of the vasculitis type, ANCA specificity, and treatment on mortality and morbidity. Medicine (Baltimore) 96:e6083CrossRef

37.

Stegeman CA, Tervaert JW, De Jong PE et al (1996) Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener’s granulomatosis. Dutch Co-Trimoxazole Wegener Study Group. N Engl J Med 335:16–20CrossRef

38.

Terrier B, Pagnoux C, Perrodeau E et al (2018) Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides. Ann Rheum Dis 77:1150–1156CrossRef

39.

Thery-Casari C, Euvrard R, Mainbourg S et al (2020) Severe infections in patients with anti-neutrophil cytoplasmic antibody-associated vasculitides receiving rituximab: A meta-analysis. Autoimmun Rev 19(5):102505CrossRef

40.

Vandenbussche C, Bitton L, Bataille P et al (2019) Prognostic value of microscopic hematuria after induction of remission in antineutrophil cytoplasmic antibodies-associated vasculitis. Am J Nephrol 49:479–486CrossRef

41.

Venhoff N, Effelsberg NM, Salzer U et al (2012) Impact of rituximab on immunoglobulin concentrations and B cell numbers after cyclophosphamide treatment in patients with ANCA-associated vasculitides. Plos One 7:e37626. https://doi.org/10.1371/journal.pone.0037626CrossRefPubMedPubMedCentral

42.

Walsh M, Flossmann O, Berden A et al (2012) Risk factors for relapse of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 64:542–548CrossRef

43.

Walsh M, Merkel PA, Mahr A et al (2010) Effects of duration of glucocorticoid therapy on relapse rate in antineutrophil cytoplasmic antibody-associated vasculitis: a meta-analysis. Arthritis Care Res 62:1166–1173CrossRef

44.

Yates M, Watts RA, Bajema IM et al (2016) EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis 75:1583–1594

Titel: ANCA-assoziierte Vaskulitiden nach Erreichen einer Remission
verfasst von: Prof. Dr. med. B. Hellmich
Publikationsdatum: 04.01.2021
Verlag: Springer Vienna
Schlagwort: Rheumatologie
Erschienen in: rheuma plus / Ausgabe 2/2021
Print ISSN: 1868-260X
Elektronische ISSN: 2191-2610
DOI: https://doi.org/10.1007/s12688-020-00391-x

Springer Medizin Österreich

Auszug

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2021

Diagnostische Fallstricke vermeiden und zielgerichtet behandeln

Epidemiologische Daten zu osteoporotischen Frakturen in Österreich

Rebellisches Gelenk – eine interdisziplinäre Aufgabe

Personalisierte Differenzialtherapie heute möglich

Knorpelschäden rechtzeitig behandeln

Fibromyalgie – pragmatisch gedacht